Adaptimmune Therapeutics Plc Stock Fundamentals
| ADAP Stock | USD 1.04 0.02 1.96% |
Adaptimmune Therapeutics Plc fundamentals help investors to digest information that contributes to Adaptimmune Therapeutics' financial success or failures. It also enables traders to predict the movement of Adaptimmune Stock. The fundamental analysis module provides a way to measure Adaptimmune Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Adaptimmune Therapeutics stock.
At this time, Adaptimmune Therapeutics' Interest Expense is relatively stable compared to the past year. As of 06/11/2024, Total Other Income Expense Net is likely to grow to about 9.7 M, while Other Operating Expenses is likely to drop slightly above 116.9 M. Adaptimmune | Select Account or Indicator |
Adaptimmune Therapeutics Plc Company Shares Outstanding Analysis
Adaptimmune Therapeutics' Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current Adaptimmune Therapeutics Shares Outstanding | 255.56 M |
Most of Adaptimmune Therapeutics' fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Adaptimmune Therapeutics Plc is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Adaptimmune Shares Outstanding Historical Pattern
Today, most investors in Adaptimmune Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Adaptimmune Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's shares outstanding growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Adaptimmune Therapeutics shares outstanding as a starting point in their analysis.
Adaptimmune Therapeutics Shares Outstanding |
| Timeline |
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
Adaptimmune Common Stock Shares Outstanding
Common Stock Shares Outstanding |
|
Based on the latest financial disclosure, Adaptimmune Therapeutics Plc has 255.56 M of shares currently outstending. This is 41.56% higher than that of the Biotechnology sector and 139.17% higher than that of the Health Care industry. The shares outstanding for all United States stocks is 55.31% higher than that of the company.
Adaptimmune Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Adaptimmune Therapeutics's current stock value. Our valuation model uses many indicators to compare Adaptimmune Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Adaptimmune Therapeutics competition to find correlations between indicators driving Adaptimmune Therapeutics's intrinsic value. More Info.Adaptimmune Therapeutics Plc is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . At this time, Adaptimmune Therapeutics' Return On Equity is relatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Adaptimmune Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Adaptimmune Shares Outstanding Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Adaptimmune Therapeutics' direct or indirect competition against its Shares Outstanding to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Adaptimmune Therapeutics could also be used in its relative valuation, which is a method of valuing Adaptimmune Therapeutics by comparing valuation metrics of similar companies.Adaptimmune Therapeutics is currently under evaluation in shares outstanding category among its peers.
Adaptimmune Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Adaptimmune Therapeutics from analyzing Adaptimmune Therapeutics' financial statements. These drivers represent accounts that assess Adaptimmune Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Adaptimmune Therapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 126.0M | 767.9M | 584.3M | 235.4M | 159.5M | 151.5M | |
| Enterprise Value | 101.0M | 734.7M | 459.8M | 150.4M | 40.7M | 38.7M |
Adaptimmune Fundamentals
| Return On Equity | -3.02 | ||||
| Return On Asset | -0.45 | ||||
| Operating Margin | (8.68) % | ||||
| Current Valuation | 1.47 B | ||||
| Shares Outstanding | 255.56 M | ||||
| Shares Owned By Insiders | 0.38 % | ||||
| Shares Owned By Institutions | 64.20 % | ||||
| Number Of Shares Shorted | 3.44 M | ||||
| Price To Earning | (7.73) X | ||||
| Price To Book | 7.50 X | ||||
| Price To Sales | 4.92 X | ||||
| Revenue | 60.51 M | ||||
| Gross Profit | (100.58 M) | ||||
| EBITDA | (127.91 M) | ||||
| Net Income | (114.31 M) | ||||
| Cash And Equivalents | 199.67 M | ||||
| Cash Per Share | 1.22 X | ||||
| Total Debt | 25.23 M | ||||
| Debt To Equity | 0.20 % | ||||
| Current Ratio | 4.00 X | ||||
| Book Value Per Share | 0.1 X | ||||
| Cash Flow From Operations | (141.43 M) | ||||
| Short Ratio | 3.30 X | ||||
| Earnings Per Share | (0.73) X | ||||
| Price To Earnings To Growth | 0.11 X | ||||
| Target Price | 2.02 | ||||
| Number Of Employees | 449 | ||||
| Beta | 2.33 | ||||
| Market Capitalization | 260.65 M | ||||
| Total Asset | 282.62 M | ||||
| Retained Earnings | (1.02 B) | ||||
| Working Capital | 134.76 M | ||||
| Current Asset | 199.54 M | ||||
| Current Liabilities | 22.66 M | ||||
| Net Asset | 282.62 M |
About Adaptimmune Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Adaptimmune Therapeutics Plc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Adaptimmune Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Adaptimmune Therapeutics Plc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 29 M | 21 M | |
| Cost Of Revenue | 9.9 M | 9.4 M | |
| Total Revenue | 60.5 M | 63.5 M | |
| Stock Based Compensation To Revenue | 0.19 | 0.18 | |
| Sales General And Administrative To Revenue | 1.19 | 1.13 | |
| Research And Ddevelopement To Revenue | 2.36 | 2.24 | |
| Capex To Revenue | (0.08) | (0.08) | |
| Revenue Per Share | 0.30 | 0.23 | |
| Ebit Per Revenue | (2.28) | (2.39) |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectAdditional Tools for Adaptimmune Stock Analysis
When running Adaptimmune Therapeutics' price analysis, check to measure Adaptimmune Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adaptimmune Therapeutics is operating at the current time. Most of Adaptimmune Therapeutics' value examination focuses on studying past and present price action to predict the probability of Adaptimmune Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adaptimmune Therapeutics' price. Additionally, you may evaluate how the addition of Adaptimmune Therapeutics to your portfolios can decrease your overall portfolio volatility.